Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

XSSC:603392 Stock Report

Market Cap: CN¥92.6b

Beijing Wantai Biological Pharmacy Enterprise Future Growth

Future criteria checks 5/6

Beijing Wantai Biological Pharmacy Enterprise is forecast to grow earnings and revenue by 113.8% and 60.9% per annum respectively. EPS is expected to grow by 113.8% per annum. Return on equity is forecast to be 17.9% in 3 years.

Key information

113.8%

Earnings growth rate

113.8%

EPS growth rate

Biotechs earnings growth43.4%
Revenue growth rate60.9%
Future return on equity17.9%
Analyst coverage

Low

Last updated25 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

XSSC:603392 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20269,9453,272N/AN/A1
12/31/20253,4032,357N/AN/A2
12/31/20242,425260N/AN/A1
9/30/20242,490-294-153845N/A
6/30/20242,713-1944921,500N/A
3/31/20243,3771289181,861N/A
12/31/20235,5111,2483781,538N/A
9/30/20237,5042,6001,0571,911N/A
6/30/20239,4193,7451,5712,578N/A
3/31/202310,9014,6502,3563,371N/A
12/31/202211,1854,7363,2034,133N/A
9/30/202210,8054,7772,8864,161N/A
6/30/20229,7163,9931,8473,025N/A
3/31/20228,0983,0638872,053N/A
12/31/20215,7502,0216341,682N/A
9/30/20214,3511,39833888N/A
6/30/20213,4751,15576725N/A
3/31/20212,86789666580N/A
12/31/20202,35467778468N/A
9/30/20201,95355142377N/A
6/30/20201,50436881356N/A
3/31/20201,24423934252N/A
12/31/20191,184209111273N/A
9/30/20191,09621773184N/A
6/30/20191,05426995186N/A
3/31/20191,007279-1164N/A
12/31/2018983293-38208N/A
12/31/2017950150N/A147N/A
12/31/2016844148N/A129N/A
12/31/2015681119N/A152N/A
12/31/2014596118N/A132N/A
12/31/201349980N/A98N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603392 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 603392 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 603392 is expected to become profitable in the next 3 years.

Revenue vs Market: 603392's revenue (60.9% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 603392's revenue (60.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603392's Return on Equity is forecast to be low in 3 years time (17.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y